The findings from NP’s mother-in law should be interesting because she doesn’t have TNBC, but another type of metastatic breast cancer. If the drug shows similar results as TNBC, it may indicate that leronlimab will work for other metastatic cancers that are CCR5 positive. That will open the flood gates for enrolling patients with different types of cancers aka the basket trial.

IMO, the BLA and licensing deal is front and center, but the cancer trial and PreP aren’t far behind. mTNBC was a 300 meter target not long ago, but it’s slowly getting closer and may present itself as a 25 meter target if the next 5-10 patients show similar results. And let’s be clear, even if this drug works in 50% of patients, that’s good news.